business / news / / MassLive
Takeda's experimental drug TAK-881 is on track for FDA review later this year.
Takeda's TAK-881 drug cleared a key clinical trial for Primary Immunodeficiency Disease treatment.
KEY POINTS
- TAK-881 provides the same immune protection as HYQVIA with half the infusion volume required.
- The new drug also significantly reduces administration time compared to current PID therapies.
- TAK-881 was successfully tested in both adults and children as young as 2 years old.
- Takeda aims to seek regulatory approval for TAK-881 in the US, EU, and Japan by fiscal year 2026.
COMPANIES
Summarized by Newsio from MassLive. How we summarize →